뉴릭스 테라퓨틱스(NRIX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $25.06 (-1.73%), 시가총액 $1.70B, 52주 최저~최고 $8.24 ~ $21.47.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B
뉴릭스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
뉴릭스 테라퓨틱스의 현재 주가는 $25.06 (-1.73%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
뉴릭스 테라퓨틱스의 시가총액은 약 $1.70B입니다.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer,